Breaking News Instant updates and real-time market news.

ABT

Abbott

, STJ

Acquired by ABT

09:26
10/19/16
10/19
09:26
10/19/16
09:26

Abbott CEO sees St. Jude Medical deal closing by year end

Abbott Laboratories (ABT) CEO Miles White said that "based on everything we know" he expects the company's deal with St. Jude (STJ) to close by year end, adding that he believes St. Jude management has handled everything it has been dealing with lately "very well" and "very thoroughly."

ABT

Abbott

STJ

Acquired by ABT

  • 19

    Oct

  • 19

    Oct

  • 21

    Oct

  • 26

    Oct

  • 06

    Nov

ABT Abbott

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
STJ Acquired by ABT

08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.

TODAY'S FREE FLY STORIES

10:45
04/25/17
04/25
10:45
04/25/17
10:45
General news
Treasury Action: yields rotated below highs »

Treasury Action: yields…

VDNRF

Vedanta Resources

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Downgrade
Vedanta Resources rating change  »

Vedanta Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPE

Expedia

$134.14

2.16 (1.64%)

10:41
04/25/17
04/25
10:41
04/25/17
10:41
Options
Notable pre-earnings option play in Expedia »

Notable pre-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 16

    May

10:40
04/25/17
04/25
10:40
04/25/17
10:40
General news
Treasury Option Action: a round of positioning »

Treasury Option Action: a…

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:39
04/25/17
04/25
10:39
04/25/17
10:39
Hot Stocks
JetBlue says fleet review 'going to take a little bit of time' »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

, SSNLF

Samsung

10:38
04/25/17
04/25
10:38
04/25/17
10:38
Periodicals
Samsung to give new MRAM memory details next month, Patently Apple says »

Following on a report…

MRAM

Everspin Technologies

$9.29

0.14 (1.53%)

SSNLF

Samsung

IBM

IBM

$161.45

0.7 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

AVXS

AveXis

$79.18

2.42 (3.15%)

10:37
04/25/17
04/25
10:37
04/25/17
10:37
Hot Stocks
AveXis says AVXS-101 appears to have favorable safety profile in Phase 1 trial »

AveXis presented results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    Jun

TSLA

Tesla

$308.03

2.43 (0.80%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Periodicals
Union workers claim Tesla illegally intimidated them, BuzzFeed says »

The United Automobile…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 30

    May

AEP

American Electric

$67.86

-0.11 (-0.16%)

10:35
04/25/17
04/25
10:35
04/25/17
10:35
Hot Stocks
American Electric says to invest $17.3B in capital over next three years »

American Electric Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 27

    Apr

10:35
04/25/17
04/25
10:35
04/25/17
10:35
General news
U.S. consumer confidence fell to a still-robust 120.3 »

U.S. consumer confidence…

FCX

Freeport McMoRan

$13.19

0.955 (7.81%)

10:34
04/25/17
04/25
10:34
04/25/17
10:34
Hot Stocks
Freeport McMoRan says near-term debt situation ins manageable »

At some point looking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, EADSY

Airbus

$20.02

0.84 (4.38%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Hot Stocks
JetBlue says early A321NEOs have Pratt & Whitney GTF engines »

JetBlue says "We…

JBLU

JetBlue

$21.75

0.22 (1.02%)

EADSY

Airbus

$20.02

0.84 (4.38%)

UTX

United Technologies

$117.06

0.74 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

BIIB

Biogen

$276.86

3.92 (1.44%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Recommendations
Biogen analyst commentary  »

With Spinraza 'just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

UNXL

Uni-Pixel

$0.80

-0.01 (-1.23%)

10:31
04/25/17
04/25
10:31
04/25/17
10:31
Options
Uni Pixel with higher call volume »

Uni Pixel with higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

10:30
04/25/17
04/25
10:30
04/25/17
10:30
General news
The 5.8% March U.S. new home sales surge »

The 5.8% March U.S. new…

EAT

Brinker

$43.93

-1.53 (-3.37%)

10:29
04/25/17
04/25
10:29
04/25/17
10:29
Hot Stocks
Brinker says 'comfortable' with guidance provided for FY17 »

Management said on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

JBLU

JetBlue

$21.75

0.22 (1.02%)

10:28
04/25/17
04/25
10:28
04/25/17
10:28
Hot Stocks
Breaking Hot Stocks news story on JetBlue »

JetBlue says committed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on JetBlue, Embraer »

JetBlue says timing…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

QQQ

PowerShares QQQ Trust

$134.16

1.6 (1.21%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Technical Analysis
PowerShares QQQ Trust hits fresh 52-week highs »

The breakout that began…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:27
04/25/17
04/25
10:27
04/25/17
10:27
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

C

Citi

$60.29

0.85 (1.43%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Citi confirms receipt of CMA license in Saudi Arabia »

The Saudi Arabian Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 31

    May

  • 25

    Jul

FCX

Freeport McMoRan

$13.15

0.9153 (7.48%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Breaking Hot Stocks news story on Freeport McMoRan »

Freeport says Indonesia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBLU

JetBlue

$21.75

0.22 (1.02%)

, ERJ

Embraer

$19.51

-0.2483 (-1.26%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
JetBlue aiming for CASM ex-fuel flat to up 1% for 2018-2020 »

JetBlue (JBLU) says…

JBLU

JetBlue

$21.75

0.22 (1.02%)

ERJ

Embraer

$19.51

-0.2483 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BBRY

BlackBerry

$9.29

0.21 (2.31%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$81.41

-2.01 (-2.41%)

10:26
04/25/17
04/25
10:26
04/25/17
10:26
Hot Stocks
Eli Lilly says hasn't contemplated scenario to not pursue baricitinib in RA »

On Eli Lilly's Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.